Folate-based thymidylate synthase inhibitors as anticancer drugs

Annals of Oncology

Volumn 6, Issue 9, 1995, Pages 871-881

  Jackman, A L ^a   Calvert, A H ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Antifolates; Thymidylate synthase

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; ENZYME INHIBITOR; METESIND GLUCURONATE; N [4 [2 (2 AMINO 4,7 DIHYDRO 4 OXOPYRROLO[2,3 D]PYRIDIN 5 YL)ETHYL]BENZOYL]GLUTAMIC ACID; NOLATREXED; PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG DESIGN; HUMAN; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FOLIC ACID; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMAN; INDOLES; QUINAZOLINES; THIOPHENES; THYMIDYLATE SYNTHASE;

EID: 0028853821     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a059353     Document Type: Review

References (84)

1. Matherly L.H. Seither R.L. Goldman I.D. The basis for antifolate cytotoxicity, selectivity and metabolic transformations: Effects on utilisation of endogenous and exogenous folate cofactors Powis G. Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents 1994 Pergamon Press Ltd Oxford UK
2. Danenberg P.V. Lockshin A. Fluorinated pyrimidines as tight-binding inhibitors of thymidylate synthetase Pharmacol Ther 13 1981 69 90
3. Evans R.M. Laskin J.D. Hakala M.T. Assessment of growth-limiting events caused by 5-fluorouracil in mouse and in human cells Cancer Res 40 1980 4113 4122
4. Aschele C. Sobero A. Faderan M.A. Bertino J.R. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules Cancer Res 52 1992 1855 1864
5. Hoskins W.J. Perez C.A. Young R.C. Gynecologic tumours DeVita V.T. Jr. Hellman S. Rosenberg S.A. Cancer, Principles and Practice of Oncology 1993 Lippincott Co. J.B. Philadelphia 1152 1225
6. Poplack D.G. Magrath I.T. Kun L.E. Pizzo P.A. DeVita V.T. Jr. Hellman S. Rosenberg S.A. Leukemias and lymphomas of childhood 1993 J.B. Lippincott Co. Philadelphia 1792 1818
7. Harris J.R. Morrow M. Bonadonna G. DeVita V.T. Jr. Hellman S. Rosenberg S.A. Cancer of the breast 1993 J.B. Lippincott Co. Philadelphia 1264 1332
8. Kohne-Wompner C-H Schmoll H-J Harstrick A. Rustum Y.M. Chemotherapeutic strategies in metastatic colorectal cancer An overview of current clinical trials Semin Oncol 19 Suppl 3 1992 105 125
9. Sotos G.A. Grogan L. Allegra C.J. Preclinical and clinical aspects of biomodulation of 5-fluorouracil Cancer Treat Rev 20 1994 11 49
10. Moertel C.G. Fleming T.R. Macdonald J.S. Fluorouracil plus Levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report Ann Intern Med 122 1995 321 326
11. Jaffe N. Frei E. III Traggis F. Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma N Engl J Med 291 1974 994 997
12. Jones T.R. Calvert A.H. Jackman A.L. A potent antitumour quinazoline inhibitor of thymidylate synthetase: Synthesis, biological properties and therapeutic results in mice Eur J Cancer 17 1981 11 19
13. Calvert A.H. Alison D.L. Harland S.J. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717 J Clin Oncol 4 1986 1245 1252
14. Alison D.L. Newell D.R. Sessa C. The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic caid (CB3717) Cancer Chemother Pharmacol 14 1985 265 271
15. Calvert A.H. Newell D.R. Jackman A.L. Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) NCI Monograph 5 1987 213 218
16. Jackman A.L. Jones T.R. Calvert A.H. Thymidylate synthase inhibitors: experimental and clinical aspects Muggia F.M. Experimental and Clinical Progress in Cancer Chemotherapy 1985 Martinus Nijhoff Boston 155 210
17. Clarke S.J. Jackman A.L. Judson I.R. The history of the development and clinical use of CB3717 and ICI D1694 Rustum Y. Proc of the International Symposium on Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation 1993 Plenum Press New York 277 287
18. Webber S.E. Bleckman T.M. Attard J. Design of thymidylate synthase inhibitors using protein crystal structures: The synthesis and biological evaluation of a novel class of 5-substituted quinazolinones J Med Chem 36 1993 733 746
19. Jackson R.C. Jackman A.L. Calvert A.H. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, CB3717, on human lymphoblastoid cells Biochem Pharmacol 32 1983 3783 3790
20. Jackman A.L. Taylor G.A. O'Connor B.M. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo Cancer Res 50 1990 5212 5218
21. Moran R.G. Colman P.D. Rosowsky A. Structural features of 4-amino folates required for substrate activity with mammalian folylpolyglutamate synthetase Mol Pharmacol 27 1985 156 166
22. Sikora E. Jackman A.L. Newell D.R. Calvert A.H. Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro Biochem Pharmacol 37 1988 4047 4054
23. Pawelczak K. Jones T.R. Kempney M. Quinazoline antifolates inhibiting thymidylate synthase: Synthesis of four oligo (L-γ-glutamyl) conjugates of N10-propargyl-5,8-dideazafolic acid and their enzyme inhibition J Med Chem 32 1989 160 165
24. Jackman A.L. Gibson W. Brown M. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Proc of the International Symposium on Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation Rustum Y. Adv Exptl Med 1993 Plenum Press New York 265 276
25. Jackman AL, Kimbell R, Brown M et al. Quinazoline thymidylate synthase inhibitors: Methods for assessing the contribution of polyglutamation to their in vitro activity. Anticancer Drug Des; in press.
26. Cantwell B.M.J. MacCaulay V. Harris A.L. Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB3717) in advanced breast cancer Eur J Cancer 24 1988 733 736
27. Bassendine M.F. Curtin N.J. Loose H. Induction of remission to hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717: A phase II study J Hepatol 4 1987 349 356
28. Harding M.J. Cantwell B.M.J. Milstead R.A.V. Phase II study of the thymidylate synthase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer Br J Cancer 57 1988 628 629
29. Jones T.R. Thornton T.J. Flinn A. Quinazoline antifolates inhibiting thymidylate synthase: 2-Desamino derivatives with enhanced solubility and potency J Med Chem 32 1989 847 852
30. Hughes L.R. Jackman A.L. Oldfield J. Quinazoline antifolate thymidylate synthase inhibitors: Alkyl, substituted alkyl, and aryl substituents in the C2 position J Med Chem 33 1990 3060 3067
31. Jackman A.L. Newell D.R. Gibson W. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583) Biochem Pharmacol 42 1991 1885 1895
32. Fry D.W. Anderson L.A. Borst M. Goldman I.D. Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and Ehrlich tumour in vivo as factors of drug sensitivity and selectivity Cancer Res 43 1983 1087 1092
33. Poser R.G. Sirotnak F.M. Chello P.L. Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo Cancer Res 41 1981 4441 4446
34. Rumberger B.G. Barrueco J.R. Sirotnak F.M. Differing specificities for 4-aminofolate analogs, of folylpolyglutamyl synthetase from tumours and proliferative intestinal epithelium of the mouse with significance for selective antitumour action Cancer Res 50 1990 4639 4643
35. Jackman AL, Kimbell R, Brown M et al. Quinazoline-based thymidylate synthase inhibitors: Relationship between structural modifications and polyglutamation. Anticancer Drug Des; in press.
36. Jackman A.L. Taylor G.A. Calvert A.H. Harrap K.R. Modulation of antimetabolite effects: Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB 3717 Biochem Pharmacol 33 1984 3269 3275
37. Jackman A.L. Taylor G.A. Gibson W. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study Cancer Res 51 1991 5579 5586
38. Stephens T.C. Smith M.N. Waterman S.E. Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidine synthase inhibitors. Chemistry and Biology of Pteridines and Folates Ayling J.E. Nair M.G. Baugh C.M. Advances in Experimental Medicine and Biology 1993 Plenum Press New York 589 592
39. Jackman A.L. Jodrell Dl Gibson W. Stephens T.C. ICI D1694, an inhibitor of thymidylate synthase for clinical study Harkness R.A. Elion G.B. Zollner N. Purine and Pyrimidine Metabolism in Man VII, Part A, pp 19–23 1991 Plenum Press New York 19 23
40. Stephens T.C. Valaccia B.E. Sheader M.L. The thymidylate synthase inhibitor ICI D1694 is superior to CB3717, 5-fluorouracil and methotrexate against a panel of human tumour xenografts Proc Am Assoc Cancer Res 32 1991 328
41. Ward W.H.J. Kimbell R. Jackman A.L. Kinetic characteristics of ICI D1694: A quinazoline antifolate which inhibits thymidyate synthase Biochem Pharmacol 43 1992 2029 2031
42. Jackman A.L. Farrugia D.C. Gibson ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer Eur J Cancer 31A 1995 1277 1282
43. Jackman A.L. Marsham P.R. Moran R.G. Thymidylate synthase inhibitors: The in vitro activity of a series of heterocyclic benzoyl ring modified 2-desanuno-2-methyl-N10-substituted-5,8-dideazafolates Adv Enzyme Regul 31 1991 13 27
44. Gibson W. Bisset G.M.F. Marsham P.R. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells Biochem Pharmacol 45 1993 863 869
45. Jackman A.L. Kelland L.R. Kimbell Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor, ZD1694 (Tomudex) in one mouse and three human cell lines Br J Cancer 71 1995 914 924
46. Aherne W. Hardcastle A. Kelland L. Jackman A. The measurement of deoxynucleotide (dNTP) pools by radioimmunoassay. Purine and Pyrimidine Metabolism in Man Sahota A. Taylor M. Advances in Experimental Medicine and Biology 1995 Plenum Press New York 801 804
47. Jodrell D.I. Newell D.R. Gibson W. The pharmacokinetics of the quinazoline antifolate ICI D1694 in mice and rats Cancer Chemother Pharmacol 28 1991 331 338
48. Jodrell D.I. Newell D.R. Morgan S.E. The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice Br J Cancer 64 1991 833 838
49. Clarke S.J. Jackman A.L. Judson I.R. The toxicity of ICI D1694 in man and mouse. Chemistry and Biology of Pteridines and Folates Ayling J.E. Nair M.G. Baugh C.M. Advances in Experimental Medicine and Biology 1993 Plenum Press New York 601 604
50. Stephens T.C. Calvete J.A. Janes D. Antitumour activity of a new thymidylate synthase inhibitor, D1694 Proc Am Assoc Cancer Res 31 1990 342
51. Clarke S.J. Ward J. de Boer M. Phase I study of the new thymidylate synthase inhibitor Tomudex (ZD1694) in patients with advanced malignancy Ann Oncol 5 Suppl 5 1994 132
52. Sorenson J.M. Jordan E. Grem J.L. Phase I trial of ZD1694 (Tomudex), a direct inhibitor of thymidylate synthase Ann Oncol 5 Suppl 5 1994 132
53. Cunningham D. Zalcberg J. Smith I.E. Tomudex: A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid rumours Ann Oncol 5 Suppl 8 1994 179
54. Zalcberg J. Cunningham D. Green M. The final results of a large phase II study of the potent thymidylate synthase inhibitor Tomudex (ZD1694) in advanced colorectal cancer Proc ASCO 14 1995 204
55. Kerr D. Cunningham D. Zalcberg J. Tomudex (ZD1694) has superior response and toxicity profiles compared to 5-fluorouracil and LV in advanced colorectal cancer: First results of a large international phase III study Br J Cancer 72 Suppl XV 1995 10
56. Taylor E.C. Kuhnt D. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase J Med Chem 35 1992 4450 4454
57. Grindey G.B. Shih C. Barnett LY231514, a novel pyrrolo-pyrimidine antifolate that inhibits thymidylate synthase Proc Am Assoc Cancer Res 33 1992 411
58. Rinaldi D.A. Burris H.A. Dorr F.A. A phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, in patients with advanced solid tumours Proc ASCO 13 1994 159
59. Vasey P.A. Calvert A.H. Kaye S.B. Cassidy J. Clinical phase I study of LY231514 (an inhibitor of thymidylate synthase) using a daily × 5 q 21 schedule Ann Oncol 5 Suppl 5 1994 131
60. Rinaldi D. Burris H. Dorr F. A phase I evaluation of LY231514 administered every 21 days, utilising the modified continual reassessment method for dose escalation Proc ASCO 14 1995 474
61. Webber S. Johnston A. Shetty B. Preclinical studies on AG-337, a novel lipophilic thymidylate synthase inhibitor Proc Am Assoc Cancer Res 34 1993 273
62. Varney M.D. Marzoni G.P. Palmer C.L. Crystal-structure-based design and synthesis of benz[cd]indole-containing inhibitors of thymidylate synthase J Med Chem 35 1992 663 676
63. O'Connor B.M. Webber S. Jackson R.C. Biological activity of a novel rationally designed lipophilic thymidylate synthase inhibitor Cancer Chemother Pharmacol 34 1994 225 229
64. Webber S. Shetty B. Johnston A. In vitro properties and antitumour activity of AG-331, a novel lipophilic thymidylate synthase inhibitor Proc Am Assoc Cancer Res 33 1992 413
65. Rafi I. Taylor G.A. Balmanno K. A phase I study of the novel antifolate 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by a 24 intravenous continuous infusion Ann Oncol 5 Suppl 5 1994 131
66. Calvete J.A. Balmanno K. Taylor G.A. Pre-clinical and clinical studies of prolonged administration of the novel thymidylate synthase inhibitor. AG337 Proc Am Assoc Cancer Res 35 1994 306
67. Rafi I. Taylor G.A. Calvete J.A. A phase I clinical study of the novel antifolate AG337 given by 5 day continuous infusion Br J Cancer 71 Suppl XXIV 1995 10
68. Clendennin N.J. Peterkin J.J. Webber S. AG331, a 'non-classical', lipophilic thymidylate synthase inhibitor for the treatment of solid tumours Ann Oncol 5 Suppl 5 1994 133
69. Giantonio B. Qian M. Gallo J. Phase I trial of AG331 as a 5-day continuous infusion Proc ASCO 14 1995 480
70. Pendagast W. Johnson J.V. Dickerson S.H. Benzoquinazoline inhibitors of thymidylate synthase: Enzyme inhibitory activity and cytotoxicity of some 3-amino- and 3-methylbenzo[f]quinazolin-1(2H)-ones J Med Chem 36 1993 2279 2291
71. Duch D.S. Banks S. Dev I.K. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase Cancer Res 53 1993 810 818
72. Dev I.K. Dallas W.S. Ferone R. Mode of binding of folate analogs to thymidylate synthase J Biol Chem 269 1994 1873 1882
73. Ferone R. Hanlon M.H. Waters K.A. Dev I.K. Influence of intracellular polyglutamation on the cytotoxicity of the thymidylate synthase inhibitor 1843U89 Proc Am Assoc Cancer Res 34 1993 274
74. McGuire J.J. Heitzman K.J. Haile W.H. Studies on the cross-resistance of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines. Chemistry and Biology of Pteridines and Folates Ayling J.E. Nair M.G. Baugh C.M. Advances in Experimental Medicine and Biology 1993 Plenum Press New York 667 670
75. Humphreys J. Smith G. Waters K. Duch D. Antitumour activity of the novel thymidylate synthase inhibitor 1843U89 in cells resistant to antifolates by multiple mechanisms Proc Am Assoc Cancer Res 34 1993 273
76. Wilson H.R. Heath L.S. Knick V.C. In vivo antitumour activity of 1843U89, a new antifolate thymidylate synthase inhibitor Proc Am Assoc Cancer Res 33 1992 407
77. Wardleworth J.M. Boyle F.T. Barker R.J. ZD9331, The design and synthesis of a novel non-polyglutamatable TS inhibitor Ann Oncol 5 Suppl 5 1994 247
78. Boyle F.T. Wardleworth J.M. Hennequin L.F. ZD9331 — Design of a novel non-polyglutamatable quinazoline-based inhibitor of thymidylate synthase Proc Am Assoc Cancer Res 35 1994 302
79. Jackman A.L. Kimbell R. Brown M. The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor. Purine and Pyrimidine Metabolism in Man Sahota A. Taylor M. Advances in Experimental Medicine and Biology 1995 Plenum Press New York 185 188
80. Jackman A.L. Aherne G.W. Kimbell R. ZD9331, A non-polyglutamatable quinazoline thymidylate synthase inhibitor Proc Am Assoc Cancer Res 35 1994 301
81. Stephens T.C. Smith M.N. McCloskey M.L. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor In vivo antitumour efficacy and toxicity to normal murine tissues Proc Am Assoc Cancer Res 35 1994 305
82. Sirotnak F.M. DeGraw J.I. Moccio D.M. New folate analogues of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties Cancer Chemother Pharmacol 12 1984 18 25
83. Jackman A.L. Farrugia D.C. Clarke S.J. Delayed rescue of ZD1694 toxicity in Balb.c mice with thymidine or Leucovorin Proc Am Assoc Cancer Res 36 1995 377
84. Smith G.K. Duch D.S. Ferone R. Enhanced antitumour selectivity for 1843U89 through decreased host toxicity with oral folic acid Proc Am Assoc Cancer Res 36 1995 376